System for delivering an intraluminal endoprostheses and method for producing such a system

摘要

#CMT# #/CMT# A system comprises an intraluminal endoprosthesis (30) and a catheter with a balloon (10). The balloon shows an airfoil (12) in non-dilated state. A pharmaceutically active substance (20) is arranged in a carrier or multiple carriers, which are arranged under an airfoil or multiple airfoils of the balloon, where the airfoil is adhered by using the pharmaceutical active substance. The intraluminal endoprosthesis is designed as a biodegradable stent, particularly absorbable metal stent, which is crimped on the balloon. #CMT# : #/CMT# An independent claim is included for a method for producing the system, which involves introducing pharmaceutically active substance in the carrier or outer surface of the balloon by dipping, spraying, brushing or pressing. #CMT#USE : #/CMT# System for delivering an intraluminal endoprosthesis, particularly stent into a body cavity. #CMT#ADVANTAGE : #/CMT# The system limits the release of a pharmaceutically active substance, when introduced in the intraluminal endoprosthesis, and is producible in a simple and cost-effective manner. #CMT#DESCRIPTION OF DRAWINGS : #/CMT# The drawing shows a cross-sectional view of the system. 10 : Balloon 12 : Airfoil 14 : Inner sheath 16 : Outer surface of airfoil 30 : Intraluminal endoprosthesis #CMT#ORGANIC CHEMISTRY : #/CMT# Preferred Components: The intraluminal endoprosthesis is provided with a readily releasable luminal coating, preferably one or multiple substances selected from sugar, polysaccharides, glycans, glucose, glycogen, amylose, amylopectin, chitin, callose, cellulose, fats, cholesterol, cholesterol, palm oil, hydrogenated soybean oils or saturated oils. The pharmaceutically active substance has Taxol(RTM: Chemotherapy drug for treating cancer) or taxane, particularly paclitaxel or sirolimus or an agent containing a hyperplastic with a distribution coefficient of 0.5 between butanol and water. The pharmaceutical active substance is applied on the balloon before the arrangement of the intraluminalen endoprosthesis by using a solvent, polymer or polymer-like substance, where the solvent is selected from dimethyl sulfoxide (DMSO), acetone, ether (di-ethylether), methanol, isopropanol or ester. #CMT#POLYMERS : #/CMT# Preferred Components: The polymer or a polymer-similar substance is selected from hyaluronic acid, prolyl 4-hydroxylase, beta -subunit (P4HB), polyvinylpyrrolidone, liposome, nanoparticle, silk proteins or cyclodextrin.